IP Library Granted Patent US 10,342,848
Granted Patent B2
US 10,342,848 · App. 15/381,680 · Granted Jul 9, 2019

Agonists of guanylate cyclase and their uses

Inventors: Dennis Riff (Laguna Beach, CA); Gary S. Jacob (New York, NY); Kunwar Shailubhai (Audubon, PA); Patrick H. Griffin (New York, NY)
Assignee: BAUSCH HEALTH IRELAND LIMITED
A61K38/10A61K9/2873A61K31/192A61K31/194A61K31/352A61K31/4468A61K31/501A61K31/519A61K31/53A61K31/7004A61K33/42A61K38/04A61K38/12A61K45/06Y02A50/473
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,342,848
App. No.
15/381,680
Granted
Jul 9, 2019
Kind
B2
Abstract

This invention provides a method of colonic cleansing.

Claims (12)

1. A method of colonic cleansing, comprising administering to a subject in need thereof a unit dose of 0.01 mg to 60 mg of an effective amount of a guanylate cyclase receptor agonist (GCRA) peptide consisting essentially of the sequence of SEQ ID NO: 1.

2. The method of claim 1 , wherein said peptide is bicyclic consisting essentially of the sequence of SEQ ID NO: 1.

3. The method of claim 1 , further comprising administering to said subject an effective amount of an osmotic colonic evacuant.

4. The method of claim 2 , wherein said osmotic colonic evacuant is magnesium citrate.

5. The method of claim 2 , wherein said osmotic colonic evacuant is a phosphate salt laxative.

6. The method of claim 1 , further comprising administering to said subject an effective amount of L-glucose, lubiprostone (Amitiza), prucalopride, an agent for treating chronic constipation, or any combination thereof.

7. The method of claim 6 , wherein said effective amount of L-glucose is a unit dose of 20g-200g.

8. The method of claim 1 , further comprising administering to said subject an effective amount of a cGMP-specific phosphodiesterase inhibitor.

9. The method of claim 8 , wherein said cGMP-specific phosphodiesterase inhibitor is selected from the group consisting of sulindac sulfone, zaprinast, motapizone, vardenafil, and sildenafil.

10. A method of colonic cleansing, comprising administering to a subject in need thereof a formulation comprising a mixture of:

a. a composition comprising an inert carrier coated with GCRA peptides consisting essentially of the sequence of SEP ID NO: 1, wherein said composition comprises an enteric coating that releases the peptides at pH 5.0; and

b. a composition comprising an inert carrier coated with GCRA peptides consisting essentially of the sequence of SEQ ID NO: 1, wherein said composition comprises and enteric coating that releases the peptides at pH 6.0or pH 7.0.

Assignments (15)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061882/0708 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062078/0276 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 57287/0160) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061874/0539 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
SECURITY INTEREST Recorded Aug 25, 2021
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH+LOMB IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 057287/0140 →
SECURITY INTEREST Recorded Aug 25, 2021
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH+LOMB IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057287/0160 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2019
From: SYNERGY PHARMACEUTICALS INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 049297/0683 →
RELEASE OF SECURITY INTEREST Recorded Mar 6, 2019
From: CRG SERVICING LLC
To: SYNERGY PHARMACEUTICALS INC.
Reel/Frame 048521/0005 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2018
From: RIFF, DENNIS; JACOB, GARY S.; SHAILUBHAI, KUNWAR; GRIFFIN, PATRICK H.
To: SYNERGY PHARMACEUTICALS, INC.
Reel/Frame 047763/0690 →
SECURITY INTEREST Recorded Sep 5, 2017
From: SYNERGY PHARMACEUTICALS INC.
To: CRG SERVICING LLC, AS AGENT
Reel/Frame 043488/0741 →
Continuity (3)
Continuation 14189645 · Feb 25, 2014
Provisional Application 61768902 · Feb 25, 2013
Related Publication 20170143789A1 · May 25, 2017